 |
|
daclizumab
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | anti-Tac
Anti-Tac Humanized Monoclonal Antibody
anti-Tac monoclonal antibody
Dacliximab | | | | US brand name: | | Zenapax | | | | Abbreviation: | | MOAB anti-Tac | | |
|
|
